Alopecia Areata Epidemiology Forecast 2025-2034

Alopecia areata, also known as patchy hair loss, refers to an autoimmune disease that attacks the hair follicles in the body. It is estimated that around 1 in 50 individuals will be affected by alopecia areata at some point in their lives. The skin condition can develop at any age and occurs in both men and women equally.

Alopecia Areata Epidemiology Forecast Report Coverage

The “Alopecia Areata Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of alopecia areata. It projects the future incidence and prevalence rates of alopecia areata across various populations. The study covers age, gender, and type as major determinants of the alopecia areata-affected population. The report highlights patterns in the prevalence of alopecia areata over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of alopecia areata in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Alopecia Areata Disease Overview

Alopecia areata refers to a chronic autoimmune condition in which the immune system starts attacking hair follicles, disrupting normal hair growth. It can cause patchy hair loss on the scalp, face, and sometimes other parts of the body. The condition can also lead to complete hair loss on the scalp (alopecia totalis) or the entire body (alopecia universalis). The exact cause of alopecia areata is unknown. Studies suggest genetic predisposition, stress, infections, and environmental factors may trigger the condition.

Alopecia Areata: Treatment Overview

There is no definitive cure for alopecia areata, with the treatment focusing on stimulating hair regrowth and managing symptoms. Common treatments include anti-inflammatory medications that are applied directly to the affected areas to suppress immune activity in the hair follicles. Minoxidil, commonly known as Rogaine, promotes hair regrowth and helps in the treatment of alopecia areata. Oral medications such as corticosteroids and emerging drugs like tofacitinib and ruxolitinib are also used as treatment options.

Epidemiology

The alopecia areata epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for alopecia areata by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for alopecia areata and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Alopecia areata is reported to affect men and women of all races equally, with around 1 in 50 individuals suffering from the skin condition at some point in their lives.
• Studies show that the risk of alopecia areata increases if an individual has a close relative with the condition. It is estimated that approximately 20% of alopecia areata patients have at least one affected family member.
• In the general population, the lifetime risk of developing alopecia areata is approximately 2%, with an estimated prevalence of about 1 in 1000. The mean age of onset of this immune-mediated autoimmune disorder is 32 years for men and 36 years for women.
• People with alopecia areata experience a 16% higher risk of developing other autoimmune diseases, such as thyroid disease, vitiligo, and lupus. Additionally, 39% of alopecia areata patients also have atopic dermatitis, a type of eczema.

Country-wise Alopecia Areata Epidemiology

The alopecia areata epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of alopecia areata varies between countries owing to differences in genetics, environmental exposures, and the availability and quality of healthcare services. Stress, infections, or changes in climate are also reported to affect the onset and severity of alopecia areata. In the United States, around 2.5 million people are affected by alopecia areata.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of alopecia areata based on several factors.
• Alopecia Areata Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of alopecia areata are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of alopecia areata epidemiology in the 8 major markets?
• What will be the total number of patients with alopecia areata across the 8 major markets during the forecast period?
• What was the country-wise prevalence of alopecia areata in the 8 major markets in the historical period?
• Which country will have the highest number of alopecia areata patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of alopecia areata during the forecast period of 2025-2034?
• What are the currently available treatments for alopecia areata?
• What are the disease risks, signs, symptoms, and unmet needs of alopecia areata?

This product will be delivered within 3-5 business days.